The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Corneal Neovascularization: An Anti-VEGF Therapy Review
Open accessAbstract
Corneal neovascularization is a serious condition that can lead to a profound decline in vision. The abnormal vessels block light, cause corneal scarring, compromise visual acuity, and may lead to inflammation and edema. Corneal neovascularization occurs when the balance between angiogenic and antiangiogenic factors is tipped toward angiogenic molecules. Vascular endothelial growth factor (VEGF), one of the most important mediators of angiogenesis, is upregulated during neovascularization. In fact, anti-VEGF agents have efficacy in the treatment of neovascular age-related macular degeneration, diabetic retinopathy, macular edema, neovascular glaucoma, and other neovascular diseases. These same agents have great potential for the treatment of corneal neovascularization. We review some of the most promising anti-VEGF therapies, including bevacizumab, VEGF trap, siRNA, and tyrosine kinase inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., & Mello, C. C. (1998) · Nature · doi:10.1038/35888 · Cited by 15,429
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Killing the messenger: short RNAs that silence gene expression
Dykxhoorn, D. M., Novina, C. D., & Sharp, P. A. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1129 · Cited by 1,182
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Cursiefen, C., Chen, L., Borges, L. P., Jackson, D. G., Cao, J., Radziejewski, C. H., D'Amore, P. A., Dana, M. R., Wiegand, S. J., & Streilein, J. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420465 · Cited by 1,059
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
Ferrara, N., Hillan, K. J., & Novotny, W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.05.132 · Cited by 977
Anatomy and physiology of the cornea
DelMonte, D. W., & Kim, T. (2011) · Journal of Cataract and Refractive Surgery · doi:10.1016/j.jcrs.2010.12.037 · Cited by 871
Ocular immune privilege: therapeutic opportunities from an experiment of nature
Streilein, J. W. (2003) · Nature Reviews Immunology · doi:10.1038/nri1224 · Cited by 807
Corneal avascularity is due to soluble VEGF receptor-1
Ambati, B. K., Nozaki, M., Singh, N., Takeda, A., Jani, P. D., Suthar, T., Albuquerque, R. J. C., Richter, E., Sakurai, E., Newcomb, M. T., et al. (2006) · Nature · doi:10.1038/nature05249 · Cited by 684
SPAIDE, R. F., LAUD, K., FINE, H. F., KLANCNIK, J. M., MEYERLE, C. B., YANNUZZI, L. A., SORENSON, J., SLAKTER, J., FISHER, Y. L., & COONEY, M. J. (2006) · Retina · doi:10.1097/00006982-200604000-00001 · Cited by 630
Chang, J.-H., Gabison, E. E., Kato, T., & Azar, D. T. (2001) · Current Opinion in Ophthalmology · doi:10.1097/00055735-200108000-00002 · Cited by 546
Self-citationFung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Maguire, M. G., Stark, W. J., Gottsch, J. D., Stulting, R. D., Sugar, A., Fink, N. E., & Schwartz, A. (1994) · Ophthalmology · doi:10.1016/s0161-6420(94)31138-9 · Cited by 466
Lee, P., Wang, C. C., & Adamis, A. P. (1998) · Survey of Ophthalmology · doi:10.1016/s0039-6257(98)00035-6 · Cited by 464
Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor
Roskoski, R. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.02.156 · Cited by 412
Predicted biological activity of intravitreal VEGF Trap
Stewart, M. W., & Rosenfeld, P. J. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.134874 · Cited by 375
Amano, S., Rohan, R. M., Kuroki, M., Tolentino, M. J., & Adamis, A. P. (1998) · PubMed · Cited by 337
Cursiefen, C., Cao, J., Chen, L., Liu, Y., Maruyama, K., Jackson, D., Kruse, F. E., Wiegand, S. J., Dana, M. R., & Streilein, J. W. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-1380 · Cited by 329
Jo, N., Mailhos, C., Ju, M., Cheung, E., Bradley, J., Nishijima, K., Robinson, G. S., Adamis, A. P., & Shima, D. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050588 · Cited by 322
Systemic and Ocular Safety of Intravitreal Anti-VEGF Therapies for Ocular Neovascular Disease
Tolentino, M. (2011) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.08.006 · Cited by 304
Homologs of vascular endothelial growth factor are encoded by the poxvirus orf virus
Lyttle, D. J., Fraser, K. M., Fleming, S. B., Mercer, A. A., & Robinson, A. J. (1994) · Journal of Virology · doi:10.1128/jvi.68.1.84-92.1994 · Cited by 303
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/j.ohc.2006.05.009 · Cited by 299
Cationic liposome-mediated delivery of siRNAs in adult mice
Sioud, M., & Sørensen, D. R. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.057 · Cited by 286
Nomoto, H., Shiraga, F., Kuno, N., Kimura, E., Fujii, S., Shinomiya, K., Nugent, A. K., Hirooka, K., & Baba, T. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-3148 · Cited by 269
The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema
Do, D. V., Schmidt-Erfurth, U., Gonzalez, V. H., Gordon, C. M., Tolentino, M., Berliner, A. J., Vitti, R., Rückert, R., Sandbrink, R., Stein, D., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.018 · Cited by 253
Corneal Lymphangiogenesis: Evidence, Mechanisms, and Implications for Corneal Transplant Immunology
Cursiefen, C., Chen, L., Dana, M. R., & Streilein, J. W. (2003) · Cornea · doi:10.1097/00003226-200304000-00021 · Cited by 246
The Effect of Topical Bevacizumab on Corneal Neovascularization
Kim, S. W., Ha, B. J., Kim, E. K., Tchah, H., & Kim, T.-I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.02.013 · Cited by 239
Kim, B., Tang, Q., Biswas, P. S., Xu, J., Schiffelers, R. M., Xie, F. Y., Ansari, A. M., Scaria, P. V., Woodle, M. C., Lu, P., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63267-1 · Cited by 234
Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)
Manzano, R. P. A., Peyman, G. A., Khan, P., Carvounis, P. E., Kivilcim, M., Ren, M., Lake, J. C., & Chevez-Barrios, P. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.107912 · Cited by 220
Tufail, A., Patel, P. J., Egan, C., Hykin, P., da Cruz, L., Gregor, Z., Dowler, J., Majid, M. A., Bailey, C., Mohamed, Q., et al. (2010) · BMJ · doi:10.1136/bmj.c2459 · Cited by 213
Dastjerdi, M. H. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.18 · Cited by 201
Complications in patients after intravitreal injection of bevacizumab
Shima, C., Sakaguchi, H., Gomi, F., Kamei, M., Ikuno, Y., Oshima, Y., Sawa, M., Tsujikawa, M., Kusaka, S., & Tano, Y. (2008) · Acta Ophthalmologica · doi:10.1111/j.1600-0420.2007.01067.x · Cited by 200
Zheng, M., Deshpande, S., Lee, S., Ferrara, N., & Rouse, B. T. (2001) · Journal of Virology · doi:10.1128/jvi.75.20.9828-9835.2001 · Cited by 197
Novel aspects of corneal angiogenic and lymphangiogenic privilege
Ellenberg, D., Azar, D. T., Hallak, J. A., Tobaigy, F., Han, K. Y., Jain, S., Zhou, Z., & Chang, J.-H. (2010) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.01.002 · Cited by 197
Self-citationDalal, R. P., MacPhail, C., Mqhayi, M., Wing, J., Feldman, C., Chersich, M. F., & Venter, W. D. F. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815b833a · Cited by 197
RNAi-Based Treatment for Neovascular Age-Related Macular Degeneration by Sirna-027
Kaiser, P. K., Symons, R. C. A., Shah, S. M., Quinlan, E. J., Tabandeh, H., Do, D. V., Reisen, G., Lockridge, J. A., Short, B., Guerciolini, R., et al. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.02.006 · Cited by 195
König, Y., Bock, F., Horn, F. K., Kruse, F. E., Straub, K., & Cursiefen, C. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1099-1 · Cited by 177
Subconjunctival Bevacizumab Injection for Corneal Neovascularization
Bahar, I., Kaiserman, I., McAllum, P. J., Rootman, D., & Slomovic, A. R. (2008) · Cornea · doi:10.1097/ico.0b013e318159019f · Cited by 158
NGUYEN, Q., SHAH, S., Hafiz, G., Quinlan, E., SUNG, J., CHU, K., Cedarbaum, J. M., & Campochiaro, P. A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.055 · Cited by 157
Heier, J. S., Boyer, D. S., Nguyen, Q. D., Marcus, D. M., Roth, D. B., Yancopoulos, G. D., Stahl, N., Ingerman, A., Vitti, R., Berliner, A. J., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.03.020 · Cited by 156
Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA
Fattal, E., & Bochot, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.07.020 · Cited by 152
Bachmann, B. O. (2008) · Archives of Ophthalmology · doi:10.1001/archopht.126.1.71 · Cited by 145
Lee, S., Zheng, M., Kim, B., & Rouse, B. T. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15755 · Cited by 143
VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration
Dixon, J. A., Oliver, S. C. N., Olson, J. L., & Mandava, N. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903201684 · Cited by 137
Singerman, L. J., Masonson, H., Patel, M., Adamis, A. P., Buggage, R. R., Cunningham, E. T., Goldbaum, M., Katz, B., & Guyer, D. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.132597 · Cited by 132
Singh, N., Higgins, E., Amin, S. H., Jani, P. D., Richter, E. R., Patel, A., Kaur, R., Wang, J., Ambati, J., Dong, Z., et al. (2006) · Cornea · doi:10.1097/ico.0b013e31802b4201 · Cited by 119
Anti-VEGF therapy: comparison of current and future agents
Pieramici, D. J., & Rabena, M. (2008) · Eye · doi:10.1038/eye.2008.88 · Cited by 112
Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model
Papathanassiou, M., THEODOSSIADIS, P. G., Liarakos, V. S., ROUVAS, A. A., Giamarellos‐Bourboulis, E. J., & Vergados, I. A. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.11.003 · Cited by 112
Lee, S., Zheng, M., Kim, B., & Rouse, B. T. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215755 · Cited by 104
Brown, D. M., Heier, J. S., Ciulla, T. A., Benz, M. S., Abraham, P., Yancopoulos, G. D., Stahl, N., Ingerman, A., Vitti, R., Berliner, A. J., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.02.039 · Cited by 100
Safety Profile of Bevacizumab on Cultured Human Corneal Cells
Yoeruek, E., Spitzer, M. S., Tatar, O., Aisenbrey, S., Bartz‐Schmidt, K. U., & Szurman, P. (2007) · Cornea · doi:10.1097/ico.0b013e3180de1d0a · Cited by 100
Cursiefen, C., Hofmann-Rummelt, C., Küchle, M., & Schlötzer-Schrehardt, U. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.87.1.101 · Cited by 99
Diana, V., Nguyen, Q. D., Shah, S. M., Browning, D. J., Haller, J. A., Chu, K. W., Yang, K., Cedarbaum, J. M., Vitti, R., Ingerman, A., et al. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.138271 · Cited by 98
Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection
Biswas, P. S., Banerjee, K., Kinchington, P. R., & Rouse, B. T. (2005) · Experimental Eye Research · doi:10.1016/j.exer.2005.05.001 · Cited by 98
Nguyen, Q. D., Shah, S. M., Browning, D. J., Hudson, H. L., Sonkin, P. L., Hariprasad, S. M., Kaiser, P. K., Slakter, J. S., Haller, J. A., & Diana, V. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.04.030 · Cited by 97
Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale
Bagri, A., Kouros‐Mehr, H., Leong, K. G., & Plowman, G. D. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.01.004 · Cited by 94
You, I. C., Kang, I., Lee, S., & Yoon, K. C. (2008) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01399.x · Cited by 82
Hosseini, H., Nejabat, M., Mehryar, M., Yazdchi, T., Sedaghat, A., & Noori, F. (2007) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2007.01572.x · Cited by 77
Kim, T., Kim, S. W., Kim, S., Kim, T., & Kim, E. K. (2008) · Cornea · doi:10.1097/ico.0b013e31815cf67d · Cited by 77
Subconjunctival Bevacizumab for Corneal Neovascularization
Doctor, P. P., Bhat, P., & Foster, C. S. (2008) · Cornea · doi:10.1097/ico.0b013e31817786ad · Cited by 77
Subconjunctival bevacizumab for vascularized rejected corneal grafts
Awadein, A. R. (2007) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2007.07.012 · Cited by 73
Dell, S., Peters, S., ̈ther, P. M., Kociok, N., & Joussen, A. M. (2006) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.05-1071 · Cited by 68
Bachmann, B. O., Luetjen-Drecoll, E., Bock, F., Wiegand, S. J., Hos, D., Dana, R., Kruse, F. E., & Cursiefen, C. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.145128 · Cited by 66
Pterygia: Pathogenesis and the Role of Subconjunctival Bevacizumab in Treatment
Mauro, J., & Foster, C. S. (2009) · Seminars in Ophthalmology · doi:10.1080/08820530902801106 · Cited by 60
Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia
Hosseini, H., Nejabat, M., & Khalili, M. R. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2007.01.047 · Cited by 55
Oh, J. Y., Kim, M. K., & Wee, W. R. (2009) · Cornea · doi:10.1097/ico.0b013e31819839f9 · Cited by 53
Hoffart, L., Matonti, F., Conrath, J., Daniel, L., Ridings, B., Masson, G. S., & Chavane, F. (2010) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2010.02252.x · Cited by 52
Yoon, K. C., Ahn, K. Y., Lee, J. H., Chun, B. J., Park, S. W., Seo, M. S., Park, Y.-G., & Kim, K. K. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302442 · Cited by 51
Murata, M., Takanami, T., Shimizu, S., Kubota, Y., Horiuchi, S., Habano, W., Ma, J., & Sato, S. (2006) · Current Eye Research · doi:10.1080/02713680500514636 · Cited by 50
Yeung, S. N., Lichtinger, A. D., Kim, P., Amiran, M. D., & Slomovic, A. R. (2011) · Cornea · doi:10.1097/ico.0b013e31821379aa · Cited by 48
de Ávila, M. P., Farah, M. E., Santos, A., Carla, L., Fuji, G., Rossi, J. V., & Nau, J. A. (2011) · Retina · doi:10.1097/iae.0b013e31822528fc · Cited by 48
Hosseini, H., & Nejabat, M. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.06.063 · Cited by 46
Takahashi, H., Obata, R., & Tamaki, Y. (2006) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2006.22.213 · Cited by 45
Dratviman‐Storobinsky, O., Avraham-Lubin, B.-C. R., Hasanreisoğlu, M., & Goldenberg‐Cohen, N. (2009) · PubMed Central · Cited by 44
The Anti-inflammatory Effect of Subconjunctival Bevacizumab on Chemically Burned Rat Corneas
Oh, J. Y., Kim, M. K., Shin, M. S., Lee, H. J., Lee, J. H., & Wee, W. R. (2009) · Current Eye Research · doi:10.1080/02713680802607740 · Cited by 41
Zuo, L., Fan, Y., Wang, F., Gu, Q., & Xu, X. (2010) · Current Eye Research · doi:10.3109/02713681003597230 · Cited by 40
Chu, H.-S., Hu, F., Yang, C., Yeh, P., Chen, Y.-M., Hou, Y., & Chen, W. (2010) · Cornea · doi:10.1097/ico.0b013e3181e458c5 · Cited by 40
Natoli, C., Perrucci, B., Perrotti, F., Falchi, L., & Iacobelli, S. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791517208 · Cited by 39
Saravia, M., Zapata, G., Ferraiolo, P., Racca, L., & Berra, A. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1101-y · Cited by 34
Krebs, I., Lie, S., STOLBA, U., Zeiler, F., Felke, S., & Binder, S. (2008) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2008.01312.x · Cited by 30
Chaoran, Z., Zhirong, L., & Xu, G. (2011) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-011-1709-6 · Cited by 25
Bevacizumab and Ocular Wound Healing After Primary Pterygium Excision
Banifatemi, M., Razeghinejad, R., Hosseini, H., & Gholampour, A. (2010) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2010.0094 · Cited by 21
Severe Corneal Changes following Intravitreal Injection of Bevacizumab
Bayar, S. A., Altınörs, D. D., Küçükerdönmez, C., & Akova, Y. A. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2010.490630 · Cited by 20
Electrocardiographic changes during subconjunctival injections
KAYIKCIOGLU, O. R., Kayıkçıoğlu, M., Erakgün, T., & Güler, C. (1999) · International Ophthalmology · doi:10.1023/a:1006486207583 · Cited by 19
Bidot, M. L., Malvitte, L., Bidot, S., Bron, A. M., & Creuzot-Garcher, C. P. (2011) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2011.03.004 · Cited by 2
Cited by
Mandal, A., Bisht, R., Rupenthal, I. D., & Mitra, A. K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.012 · Cited by 481
“Promising in-vivo results have entailed these cross-linked polymericmicelles to enter early stage clinical evaluations [14,20].”
BackgroundVascular Endothelial Growth Factor Signaling in Hypoxia and Inflammation
Ramakrishnan, S., Anand, V., & Roy, S. (2014) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-014-9531-7 · Cited by 442
Ocular drug delivery: present innovations and future challenges
Gote, V., Sikder, S., Sicotte, J., & Pal, D. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.256933 · Cited by 441
Than, A., Liu, C., Chang, H., Duong, P. K., Cheung, C. M. G., Xu, C., Wang, X., & Chen, P. (2018) · Nature Communications · doi:10.1038/s41467-018-06981-w · Cited by 345
Deng, Y., Wang, C. C., Choy, K. W., Du, Q., Chen, J., Wang, Q., Li, L., Chung, T. K. H., & Tang, T. (2014) · Gene · doi:10.1016/j.gene.2013.12.019 · Cited by 301
Metadata
- Authors
- Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T.
- Venue
- Survey of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2012-09
- Volume
- 57
- Issue
- 5
- Pages
- 415-429
- ISSN
- 0039-6257 (ISSN-L)
- OpenAlex
- W2038451782
- Cited by
- 381
- References
- 93
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.